Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Proc Natl Acad Sci U S A ; 118(26)2021 06 29.
Artigo em Inglês | MEDLINE | ID: mdl-34172583

RESUMO

Costimulation via CD137 (4-1BB) enhances antitumor immunity mediated by cytotoxic T lymphocytes. Anti-CD137 agonist antibodies elicit mild liver inflammation in mice, and the maximum tolerated dose of Urelumab, an anti-human CD137 agonist monoclonal antibody, in the clinic was defined by liver inflammation-related side effects. A protease-activated prodrug form of the anti-mouse CD137 agonist antibody 1D8 (1D8 Probody therapeutic, Pb-Tx) was constructed and found to be selectively activated in the tumor microenvironment. This construct, which encompasses a protease-cleavable linker holding in place a peptide that masks the antigen binding site, exerted antitumor effects comparable to the unmodified antibody but did not result in liver inflammation. Moreover, it efficaciously synergized with both PD-1 blockade and adoptive T-cell therapy. Surprisingly, minimal active Pb-Tx reached tumor-draining lymph nodes, and regional lymphadenectomy did not abrogate antitumor efficacy. By contrast, S1P receptor-dependent recirculation of T cells was absolutely required for efficacy. The preferential cleavage of the anti-CD137 Pb-Tx by tumor proteases offers multiple therapeutic opportunities, including neoadjuvant therapy, as shown by experiments in which the Pb-Tx is given prior to surgery to avoid spontaneous metastases.


Assuntos
Antineoplásicos/toxicidade , Antineoplásicos/uso terapêutico , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral/metabolismo , Animais , Anticorpos Monoclonais/farmacologia , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Humanos , Imunoterapia , Inflamação/patologia , Fígado/patologia , Neoplasias Pulmonares/secundário , Linfonodos/efeitos dos fármacos , Linfonodos/patologia , Camundongos , Terapia Neoadjuvante , Peptídeo Hidrolases/metabolismo
2.
Blood ; 124(11): 1832-42, 2014 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-25030062

RESUMO

Acute graft-versus-host disease (GVHD) is induced by alloreactivity of donor T cells toward host antigens presented on antigen-presenting cells (APCs). Apoptotic cells are capable of inducing tolerance by altering APC maturation. Apoptosis can be induced by extracorporeal photopheresis (ECP). We demonstrate that the use of ECP as a prophylaxis prior to conditioning significantly improves survival (P < .0001) after bone marrow transplantation (BMT) by inhibiting the initiation phase of acute GVHD in a murine BMT model. ECP-treated autologous splenocytes resulted in immune tolerance in the host, including reduced dendritic cell activation with decreased nuclear factor-κB engagement, increased regulatory T-cell (Treg) numbers with enhanced expression of cytolytic T lymphocyte-associated antigen 4, potentiating their suppressive function. The protective effect required host production of interleukin-10 and host Tregs. Conventional T cells that entered this tolerant environment experienced reduced proliferation, as well as a reduction of tissue homing and expression of activation markers. The induction of this tolerant state by ECP was obviated by cotreatment with lipopolysaccharide, suggesting that the inflammatory state of the recipient prior to treatment would play a role in potential clinical translation. The use of prophylactic ECP may provide an alternative and safe method for immunosuppression in the bone marrow transplant setting.


Assuntos
Células Apresentadoras de Antígenos/transplante , Apoptose , Doença Enxerto-Hospedeiro/prevenção & controle , Tolerância Imunológica , Animais , Células Apresentadoras de Antígenos/imunologia , Células Apresentadoras de Antígenos/patologia , Autoenxertos , Transplante de Medula Óssea , Modelos Animais de Doenças , Doença Enxerto-Hospedeiro/genética , Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/patologia , Interleucina-10/genética , Interleucina-10/imunologia , Camundongos , Camundongos Endogâmicos AKR , Camundongos Endogâmicos BALB C , Camundongos Knockout , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/patologia
3.
Blood ; 122(22): 3659-65, 2013 Nov 21.
Artigo em Inglês | MEDLINE | ID: mdl-24030387

RESUMO

To investigate the role of mast cells in hematopoietic cell transplantation, we assessed graft-versus-host disease (GVHD) in C57BL/6-Kit(W-sh/W-sh) recipients, which virtually lack mast cells, compared with C57BL/6 WT recipients. GVHD was severely exacerbated in C57BL/6-Kit(W-sh/W-sh) mice (median survival time = 13 vs 60 days in wild-type [WT] mice; P < .0001). The increased mortality risk in C57BL/6-Kit(W-sh/W-sh) hosts correlated with increased T-cell numbers in lymph nodes, liver, and gastrointestinal tract sites, as indicated by bioluminescence imaging (P < .001). We did not detect any deficit in the number or function of CD4(+)CD25(+) regulatory T cells (Tregs) in C57BL/6-Kit(W-sh/W-sh) mice. Furthermore, Tregs were equally effective at reducing GVHD in C57BL/6-Kit(W-sh/W-sh) recipients compared with WT recipients containing mast cells. Furthermore, we found that survival of C57BL/6-Kit(W-sh/W-sh) mice during GVHD was significantly improved if the mice were engrafted with bone marrow-derived cultured mast cells from WT C57BL/6 mice but not from interleukin (IL)-10-deficient C57BL/6 mice. These data indicate that the presence of mast cells can significantly reduce GVHD independently of Tregs, by decreasing conventional T-cell proliferation in a mechanism involving IL-10. These experiments support the conclusion that mast cells can mediate a novel immunoregulatory role during hematopoietic cell transplantation.


Assuntos
Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/prevenção & controle , Mastócitos/imunologia , Linfócitos T Reguladores/imunologia , Animais , Proliferação de Células , Sobrevivência Celular , Feminino , Doença Enxerto-Hospedeiro/patologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Tolerância Imunológica , Interleucina-10/biossíntese , Interleucina-10/deficiência , Interleucina-10/genética , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Masculino , Mastócitos/patologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Proteínas Proto-Oncogênicas c-kit/deficiência , Proteínas Proto-Oncogênicas c-kit/genética , Proteínas Proto-Oncogênicas c-kit/imunologia , Linfócitos T Reguladores/classificação
4.
Biol Blood Marrow Transplant ; 19(11): 1557-65, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23921175

RESUMO

Regulatory T cell (Treg) immunotherapy is a promising strategy for the treatment of graft rejection responses and autoimmune disorders. Our and other laboratories have shown that the transfer of highly purified CD4(+)CD25(+)Foxp3(+) natural Treg can prevent lethal graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation across both major and minor histocompatibility barriers. However, recent evidence suggests that the Treg suppressive phenotype can become unstable, a phenomenon that can culminate in Treg conversion into IL-17-producing cells. We hypothesized that the intense proinflammatory signals released during an ongoing alloreaction might redirect a fraction of the transferred Treg to the Th17 cell fate, thereby losing immunosuppressive potential. We therefore sought to evaluate the impact of Il17 gene ablation on Treg stability and immunosuppressive capacity in a major MHC mismatch model. We show that although Il17 gene ablation results in a mildly enhanced Treg immunosuppressive ability in vitro, such improvement is not observed when IL-17-deficient Treg are used for GVHD suppression in vivo. Similarly, when we selectively blocked IL-1 signaling in Treg, that was shown to be necessary for Th17 conversion, we did not detect any improvement on Treg-mediated GVHD suppressive ability in vivo. Furthermore, upon ex vivo reisolation of transferred wild-type Treg, we detected little or no Treg-mediated IL-17 production upon GVHD induction. Our results indicate that blocking Th17 conversion does not affect the GVHD suppressive ability of highly purified natural Treg in vivo, suggesting that IL-17 targeting is not a valuable strategy to improve Treg immunotherapy after hematopoietic cell transplantation.


Assuntos
Transplante de Medula Óssea/métodos , Doença Enxerto-Hospedeiro/imunologia , Imunoterapia Adotiva/métodos , Interleucina-17/genética , Linfócitos T Reguladores/transplante , Animais , Doença Enxerto-Hospedeiro/genética , Humanos , Interleucina-17/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Linfócitos T Reguladores/imunologia , Células Th17/imunologia
5.
Blood ; 118(8): 2342-50, 2011 Aug 25.
Artigo em Inglês | MEDLINE | ID: mdl-21734238

RESUMO

Previous work has demonstrated that both rapamycin (RAPA) and IL-2 enhance CD4⁺CD25⁺Foxp3⁺ regulatory T-cell (Treg) proliferation and function in vitro. We investigated whether the combination of RAPA plus IL-2 could impact acute GVHD induction after bone marrow transplantation (BMT). RAPA plus IL-2 resulted in improved survival and a reduction in acute GVHD lethality associated with an increased expansion of donor type CD4⁺Foxp3⁺ Tregs and reduced CD4⁺CD25⁻ conventional T cells (Tcons). RAPA plus IL-2, but not either drug alone, increased both expansion of donor natural Tregs and conversion of induced Tregs from donor CD25⁻ Tcons while IL-2 alone increased conversion of Tregs from CD25⁻ Tcon. RAPA plus IL-2 treatment resulted in less production of IFN-γ and TNF, cytokines known to be important in the initiation of acute GVHD. These studies indicate that the pharmacologic stimulation of T cells with IL-2 and the suppression of Tcon proliferation with RAPA result in a selective expansion of functional Tregs and suppression of acute GVHD.


Assuntos
Doença Enxerto-Hospedeiro/prevenção & controle , Interleucina-2/farmacologia , Sirolimo/farmacologia , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia , Doença Aguda , Animais , Transplante de Medula Óssea/efeitos adversos , Transplante de Medula Óssea/imunologia , Feminino , Fatores de Transcrição Forkhead/metabolismo , Doença Enxerto-Hospedeiro/imunologia , Interferon gama/biossíntese , Interleucina-2/administração & dosagem , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Sirolimo/administração & dosagem , Subpopulações de Linfócitos T/classificação , Subpopulações de Linfócitos T/efeitos dos fármacos , Subpopulações de Linfócitos T/imunologia , Linfócitos T Reguladores/classificação , Transplante Homólogo , Fator de Necrose Tumoral alfa/biossíntese
6.
Blood ; 117(11): 3220-9, 2011 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-21258007

RESUMO

CD4(+) natural killer T (NKT) cells, along with CD4(+)CD25(+) regulatory T cells (Tregs), are capable of controlling aberrant immune reactions. We explored the adoptive transfer of highly purified (> 95%) CD4(+)NKT cells in a murine model of allogeneic hematopoietic cell transplantation (HCT). NKT cells follow a migration and proliferation pattern similar to that of conventional T cells (Tcons), migrating initially to secondary lymphoid organs followed by infiltration of graft-versus-host disease (GVHD) target tissues. NKT cells persist for more than 100 days and do not cause significant morbidity or mortality. Doses of NKT cells as low as 1.0 × 10(4) cells suppress GVHD caused by 5.0 × 10(5) Tcons in an interleukin-4 (IL-4)-dependent mechanism. Protective doses of NKT cells minimally affect Tcon proliferation, but cause significant reductions in interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) production by donor Tcons and in skin, spleen, and gastrointestinal pathology. In addition, NKT cells do not impact the graft-versus-tumor (GVT) effect of Tcons against B-cell lymphoma-1 (BCL-1) tumors. These studies elucidate the biologic function of donor-type CD4(+)NKT cells in suppressing GVHD in an allogeneic transplantation setting, demonstrating clinical potential in reducing GVHD in HCT.


Assuntos
Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/prevenção & controle , Interleucina-4/imunologia , Células T Matadoras Naturais/citologia , Células T Matadoras Naturais/imunologia , Linfócitos T/citologia , Linfócitos T/imunologia , Doença Aguda , Transferência Adotiva , Animais , Linfócitos T CD8-Positivos/citologia , Linfócitos T CD8-Positivos/imunologia , Movimento Celular/imunologia , Proliferação de Células , Mediadores da Inflamação/metabolismo , Interferon gama/biossíntese , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Interleucina-4/biossíntese , Camundongos , Especificidade de Órgãos , Linfócitos T Reguladores/citologia , Linfócitos T Reguladores/imunologia , Fator de Necrose Tumoral alfa/biossíntese
7.
RNA ; 14(3): 577-83, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18218703

RESUMO

We report a new strategy for cell-type-specific delivery of functional siRNAs into cells. The method involves the noncovalent attachment of siRNAs to ligand-conjugated oligodeoxynucleotides via nucleic acid base-paired interactions. The resulting complexes can be directly applied to cells, leading to specific cellular uptake and gene silencing. The method is simple, economical, and can be easily adapted for other cell surface receptors. Here we show the application of this method for the delivery of siRNAs to folate receptor-expressing cells.


Assuntos
Oligodesoxirribonucleotídeos/metabolismo , RNA Interferente Pequeno/metabolismo , Pareamento de Bases , Sequência de Bases , Proteínas de Transporte/genética , Proteínas de Transporte/metabolismo , Linhagem Celular , Receptores de Folato com Âncoras de GPI , Inativação Gênica , Terapia Genética , Humanos , Proteínas Inibidoras de Apoptose , Integrina alfaV/genética , Ligantes , Proteínas Associadas aos Microtúbulos/genética , Proteínas de Neoplasias/genética , Ácidos Nucleicos/química , Ácidos Nucleicos/metabolismo , Oligodesoxirribonucleotídeos/química , Oligodesoxirribonucleotídeos/genética , RNA Mensageiro/genética , RNA Interferente Pequeno/genética , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismo , Survivina
8.
Blood ; 112(6): 2563-74, 2008 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-18565854

RESUMO

Cytokine-induced killer (CIK) cells are ex vivo-expanded T lymphocytes expressing both natural killer (NK)- and T-cell markers. CIK cells are cytotoxic against autologous and allogeneic tumors. We previously showed that adoptive transfer of allogeneic CIK cells in a murine model caused minimal graft-versus-host disease (GVHD). However, the precise mechanism of reduced GVHD is not fully understood. Therefore, we evaluated the trafficking and survival of luciferase-expressing CIK cells in an allogeneic bone marrow transplant model. The initial trafficking patterns of CIK cells were similar to conventional T cells that induced GVHD; however, CIK cells infiltrated GVHD target tissues much less and transiently. CIK cells accumulated and persisted in tumor sites, resulting in tumor eradication. We evaluated different properties of CIK cells compared with conventional T cells, demonstrating a slower division rate of CIK cells, higher susceptibility to apoptosis, persistent increased expression of interferon gamma (IFN-gamma), and reduced acquisition of homing molecules required for entry of cells into inflamed GVHD target organs that lack expression of NKG2D ligands recognized by CIK cells. Due to these properties, allogeneic CIK cells had reduced expansion and caused less tissue damage. We conclude that CIK cells have the potential to separate graft-versus-tumor effects from GVHD.


Assuntos
Transferência Adotiva/métodos , Quimiotaxia de Leucócito , Citotoxicidade Imunológica , Doença Enxerto-Hospedeiro/prevenção & controle , Células Matadoras Naturais/transplante , Linfócitos T/transplante , Transferência Adotiva/normas , Animais , Técnicas de Cultura de Células , Proliferação de Células , Sobrevivência Celular , Células Cultivadas , Citocinas/farmacologia , Doença Enxerto-Hospedeiro/etiologia , Células Matadoras Naturais/citologia , Células Matadoras Naturais/imunologia , Camundongos , Camundongos Congênicos , Camundongos Endogâmicos , Neoplasias/terapia , Linfócitos T/citologia , Linfócitos T/imunologia
9.
Int J Radiat Oncol Biol Phys ; 71(2): 559-66, 2008 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-18411004

RESUMO

PURPOSE: Human cancers frequently overexpress a high-affinity cell-surface receptor for the vitamin folic acid. Highly immunogenic haptens can be targeted to folate receptor-expressing cell surfaces by administration of folate-hapten conjugates, rendering the decorated tumor cell surfaces more recognizable by the immune system. Treatment of antihapten-immunized mice with folate-hapten constructs results in elimination of moderately sized tumors by the immune system. However, when subcutaneous tumors exceed 300 mm(3) before initiation of therapy, antitumor activity is significantly decreased. In an effort to enhance the efficacy of folate-targeted hapten immunotherapy (FTHI) against large tumors, we explored the combination of targeted hapten immunotherapy with low-dose radiotherapy. METHODS AND MATERIALS: Mice bearing 300-mm(3) subcutaneous tumors were treated concurrently with FTHI (500 nmol/kg of folate conjugated to fluorescein isothiocyanate, 20,000 U/dose of interleukin 2, and 25,000 U/dose of interferon alpha) and low-dose radiotherapy (3 Gy/dose focused directly on the desired tumor mass). The efficacy of therapy was evaluated by measuring tumor volume. RESULTS: Tumor growth analyses show that radiotherapy synergizes with FTHI in antihapten-immunized mice, thereby allowing for cures of animals bearing tumors greater than 300 mm(3). More importantly, nonirradiated distal tumor masses in animals containing locally irradiated tumors also showed improved response to hapten immunotherapy, suggesting that not all tumor lesions must be identified and irradiated to benefit from the combination therapy. CONCLUSIONS: These results suggest that simultaneous treatment with FTHI and radiation therapy can enhance systemic antitumor activity in tumor-bearing mice.


Assuntos
Proteínas de Transporte/imunologia , Haptenos/uso terapêutico , Imunoterapia/métodos , Proteínas de Neoplasias/imunologia , Receptores de Superfície Celular/imunologia , Neoplasias Cutâneas/terapia , Animais , Antineoplásicos/uso terapêutico , Terapia Combinada/métodos , Feminino , Fluoresceína-5-Isotiocianato/uso terapêutico , Receptores de Folato com Âncoras de GPI , Ácido Fólico/uso terapêutico , Haptenos/imunologia , Humanos , Interferon gama/uso terapêutico , Interleucina-2/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Radioterapia/métodos , Dosagem Radioterapêutica , Distribuição Aleatória , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/radioterapia , Carga Tumoral
11.
Cancer Cell ; 28(3): 285-95, 2015 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-26373277

RESUMO

Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the treatment of multiple cancer types. We elucidated the contribution of the fragment crystallizable (Fc) domains of anti-PD-1 and anti-PD-ligand 1 (L1) Abs for their optimal anti-tumor activity. We revealed that distinct Fcγ receptor (FcγRs) dependency and mechanisms account for the in vivo activity of anti-PD-1 versus anti-PD-L1 Abs. Anti-PD-1 Abs were found to be FcγR independent in vivo; the presence of FcγR-binding capacity compromises their anti-tumor activity. In contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcγR binding is introduced into the molecules, altering myeloid subsets within the tumor microenvironment.


Assuntos
Anticorpos/imunologia , Antígeno B7-H1/imunologia , Neoplasias/imunologia , Receptor de Morte Celular Programada 1/imunologia , Receptores de IgG/imunologia , Animais , Linhagem Celular Tumoral , Ligantes , Camundongos , Microambiente Tumoral/imunologia
12.
Adv Drug Deliv Rev ; 56(8): 1161-76, 2004 Apr 29.
Artigo em Inglês | MEDLINE | ID: mdl-15094213

RESUMO

The vitamin, folic acid, has become a useful ligand for targeted cancer therapies because it binds to a tumor-associated antigen known as the folate receptor (FR). By linking folic acid to therapeutic agents, folate-targeted cancer therapies can deliver therapeutic drugs specifically to FR-positive tumor cells. This chapter provides a summary of a specific application of folate-targeted therapies whereby folic acid is exploited to carry an attached hapten (a highly antigenic molecule) to the surfaces of tumor cells for the purpose of rendering the tumors more immunogenic. The basic strategy is to (i) saturate (label) the surface of FR-positive tumor cells with a folate-hapten conjugate against which the cancer-bearing host already has a pre-existing or induced immunity, (ii) allow the surface bound haptens to attract anti-hapten antibodies to the tumor cell surface, and (iii) stimulate Fc receptor-bearing immune cells to mount an antitumor response against the anti-hapten antibody opsonized tumor cells. In immune competent murine tumor models, hapten-marked cancer cells have been shown to be quickly recognized by antibodies and the associated Fc receptor-expressing immune cells dedicated to eliminating antibody-coated target cells. Given the need for cancer cells to escape immune surveillance in order to proliferate and survive in vivo, folate-targeted immunotherapies that mark an otherwise immunologically "invisible" cancer cell as distinctively "non-self" may provide a key strategy for combating malignant disease.


Assuntos
Proteínas de Transporte/imunologia , Sistemas de Liberação de Medicamentos/métodos , Imunoterapia/métodos , Neoplasias/terapia , Receptores de Superfície Celular/imunologia , Animais , Receptores de Folato com Âncoras de GPI , Humanos , Neoplasias/imunologia
13.
PLoS One ; 9(1): e86551, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24475140

RESUMO

Lag-3 has emerged as an important molecule in T cell biology. We investigated the role of Lag-3 in conventional T cell (Tcon) and regulatory T cell (Treg) function in murine GVHD with the hypothesis that Lag-3 engagement diminishes alloreactive T cell responses after bone marrow transplantation. We demonstrate that Lag-3 deficient Tcon (Lag-3(-/-) Tcon) induce significantly more severe GVHD than wild type (WT) Tcon and that the absence of Lag-3 on CD4 but not CD8 T cells is responsible for exacerbating GVHD. Lag-3(-/-) Tcon exhibited increased activation and proliferation as indicated by CFSE and bioluminescence imaging analyses and higher levels of activation markers such as CD69, CD107a, granzyme B, and Ki-67 as well as production of IL-10 and IFN-g early after transplantation. Lag-3(-/-) Tcon were less responsive to suppression by WT Treg as compared to WT Tcon. The absence of Lag-3, however, did not impair Treg function as both Lag-3(-/-) and WT Treg equally suppress the proliferation of Tcon in vitro and in vivo and protect against GVHD. Further, we demonstrate that allogeneic Treg acquire recipient MHC class II molecules through a process termed trogocytosis. As MHC class II is a ligand for Lag-3, we propose a novel suppression mechanism employed by Treg involving the acquisition of host MHC-II followed by the engagement of Lag-3 on T cells. These studies demonstrate for the first time the biologic function of Lag-3 expression on conventional and regulatory T cells in GVHD and identify Lag-3 as an important regulatory molecule involved in alloreactive T cell proliferation and activation after bone marrow transplantation.


Assuntos
Antígenos CD/imunologia , Transplante de Medula Óssea/efeitos adversos , Doença Enxerto-Hospedeiro/imunologia , Linfócitos T/imunologia , Transplante Homólogo/efeitos adversos , Análise de Variância , Animais , Antígenos CD/genética , Proliferação de Células , Citometria de Fluxo , Fluoresceínas , Medições Luminescentes , Camundongos , Camundongos Knockout , Succinimidas , Proteína do Gene 3 de Ativação de Linfócitos
15.
Cancer Metastasis Rev ; 27(4): 655-64, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18523731

RESUMO

Folate receptors are up-regulated on a variety of human cancers, including cancers of the breast, ovaries, endometrium, lungs, kidneys, colon, brain, and myeloid cells of hematopoietic origin. This over-expression of folate receptors (FR) on cancer tissues can be exploited to target folate-linked imaging and therapeutic agents specifically to FR-expressing tumors, thereby avoiding uptake by most healthy tissues that express few if any FR. Four folate-targeted therapeutic drugs are currently undergoing clinical trials, and several folate-linked chemotherapeutic agents are in late stage preclinical development. However, because not all cancers express FR, and because only FR-expressing cancers respond to FR-targeted therapies, FR-targeted imaging agents have been required to select patients with FR-expressing tumors likely to respond to folate-targeted therapies. This review focuses on recent advances in the use of the vitamin folic acid to target PET agents, gamma-emitters, MRI contrast agents and fluorescent dyes to FR(+) cancers for the purpose of diagnosing and imaging malignant masses with improved specificity and sensitivity.


Assuntos
Proteínas de Transporte/administração & dosagem , Diagnóstico por Imagem , Ácido Fólico/administração & dosagem , Neoplasias/diagnóstico , Compostos Radiofarmacêuticos , Receptores de Superfície Celular/administração & dosagem , Animais , Sistemas de Liberação de Medicamentos/métodos , Receptores de Folato com Âncoras de GPI , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/metabolismo
16.
AAPS J ; 8(3): E466-78, 2006 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-17025264

RESUMO

While modern genomic and proteomic technology enables rapid screening of novel proteins and peptides as potential drug candidates, design of delivery systems for these biologics remains challenging especially to achieve site-specific pharmacological actions. This article discusses the issues associated with targeted delivery of protein and peptide drugs at physiochemical, physiological, and intracellular levels with a special focus on cancer therapy.


Assuntos
Peptídeos/administração & dosagem , Proteínas/administração & dosagem , Animais , Portadores de Fármacos , Sistemas de Liberação de Medicamentos , Humanos , Neoplasias/tratamento farmacológico , Peptídeos/classificação , Proteínas/classificação
17.
Int J Cancer ; 116(5): 710-9, 2005 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-15828051

RESUMO

We previously exploited the frequent overexpression of folate receptors on cancer cells to decorate malignant cell surfaces selectively with folate-hapten conjugates. In antihapten-immunized hosts, this targeted localization of foreign haptens to tumor cells led to rapid accumulation of autologous antihapten IgG, which in turn yielded potent antitumor activity upon stimulation with cytokines (IL-2, IFN-alpha). In an effort to understand the effector mechanisms responsible for tumor regression, we have now investigated the involvement of both humoral and cellular immune components in the tumor destruction process. We report that the dependence of therapeutic efficacy on folate-hapten concentration is bimodal, suggesting that the conjugate must bridge between a cell surface FR and an antihapten IgG in order to mediate killing. Studies with cancer cells in vitro further demonstrate that folate-fluorescein-marked tumor cells are killed primarily by antibody-dependent cellular cytotoxicity and phagocytosis, with no contribution from complement-dependent mechanisms. Investigations of specific immune cell involvement also reveal that asialo-GM1(+)-natural killer cells, macrophages, CD4+ T cells and CD8+ T cells contribute significantly to recognition/removal of the cancer mass, and that elimination of these cell types markedly compromises the therapy. Because the initial antibody-dependent stage of tumor cell killing is shown to lead to a long-term antibody-independent cellular immunity that involves both CD4+ and CD8+ T cells, we propose that F(c) receptor-expressing immune cells not only initiate destruction of the IgG-marked tumor cells, but also participate in presentation of endogenous tumor antigens in a manner that leads to long-term cellular immunity.


Assuntos
Ácido Fólico/imunologia , Haptenos/imunologia , Neoplasias Experimentais/terapia , Animais , Citotoxicidade Celular Dependente de Anticorpos , Proteínas de Transporte/imunologia , Feminino , Fluoresceína-5-Isotiocianato , Receptores de Folato com Âncoras de GPI , Imunoglobulina G/sangue , Memória Imunológica , Células Matadoras Naturais/imunologia , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Neoplasias Experimentais/imunologia , Fagocitose , Receptores de Superfície Celular/imunologia , Linfócitos T/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA